TD Waterhouse Canada Inc. Buys 1,682 Shares of United Therapeutics Co. (NASDAQ:UTHR)

TD Waterhouse Canada Inc. raised its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 862.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,877 shares of the biotechnology company's stock after purchasing an additional 1,682 shares during the quarter. TD Waterhouse Canada Inc.'s holdings in United Therapeutics were worth $662,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in UTHR. Wealthfront Advisers LLC boosted its position in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the period. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $151,764,000. FMR LLC grew its stake in shares of United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after purchasing an additional 393,777 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in United Therapeutics by 1,325.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock valued at $72,085,000 after purchasing an additional 189,967 shares during the period. Finally, AustralianSuper Pty Ltd raised its position in United Therapeutics by 577.1% during the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock valued at $66,962,000 after purchasing an additional 161,751 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total value of $3,121,580.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at $10,437,712.18. This represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 74,500 shares of company stock valued at $24,472,050. 11.90% of the stock is owned by insiders.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent analyst reports. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Finally, Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a report on Monday, April 21st. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $390.17.

United Therapeutics Stock Down 1.2 %

Shares of UTHR stock traded down $3.69 during trading hours on Wednesday, hitting $297.07. 412,766 shares of the company's stock traded hands, compared to its average volume of 448,156. The stock has a market cap of $13.34 billion, a price-to-earnings ratio of 13.05, a PEG ratio of 0.97 and a beta of 0.63. The stock's fifty day simple moving average is $305.66 and its two-hundred day simple moving average is $345.68. United Therapeutics Co. has a 12-month low of $233.31 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the business earned $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.